Scinai Immunotherapeutics Ltd.

NasdaqCM:SCNI Stock Report

Market Cap: US$3.0m

Scinai Immunotherapeutics Management

Management criteria checks 3/4

Scinai Immunotherapeutics' CEO is Amir Reichman, appointed in Mar 2021, has a tenure of 3.67 years. total yearly compensation is $927.00K, comprised of 56.1% salary and 43.9% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $8.50K. The average tenure of the management team and the board of directors is 4.4 years and 4.7 years respectively.

Key information

Amir Reichman

Chief executive officer

US$927.0k

Total compensation

CEO salary percentage56.1%
CEO tenure3.7yrs
CEO ownership0.3%
Management average tenure4.4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Nov 10
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Bionvax Pharmaceuticals GAAP EPS of -NIS0.02

Aug 25

BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan

Aug 10

We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

Mar 31
We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering

Jan 29

CEO Compensation Analysis

How has Amir Reichman's remuneration changed compared to Scinai Immunotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$5m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$927kUS$520k

-US$6m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$1mUS$368k

-US$6m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022n/an/a

-US$8m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$1mUS$664k

-US$8m

Compensation vs Market: Amir's total compensation ($USD927.00K) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Amir's compensation has been consistent with company performance over the past year.

CEO

Amir Reichman (48 yo)

3.7yrs

Tenure

US$927,000

Compensation

Mr. Amir Reichman M.Sc, M.B.A, has been the Chief Executive Officer at Scinai Immunotherapeutics Ltd. (formerly known as BiondVax Pharmaceuticals Ltd.) since March 02, 2021 and has been its Director since...

Leadership Team

NamePositionTenureCompensationOwnership
Amir Reichman
CEO & Director3.7yrsUS$927.00k0.29%
$ 8.5k
Uri Ben-Or
Chief Financial Officer17.8yrsUS$174.00kno data
Elad Mark
Chief Operating Officer5.2yrsUS$265.00kno data
Dalit Fischer
Chief Technology Officerless than a yearUS$232.00kno data
Tamar Ben-Yedidia
Chief Scientist20.8yrsUS$297.00kno data
Liat Halpert
Head of Business Development & Salesless than a yearno datano data
Merav Kamensky
Head of Quality Controlno datano datano data

4.4yrs

Average Tenure

53yo

Average Age

Experienced Management: SCNI's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Amir Reichman
CEO & Director3.8yrsUS$927.00k0.29%
$ 8.5k
Adi Raviv
Independent Director4.7yrsUS$92.19k0.0039%
$ 117.0
Morris Laster
Independent Director7yrsUS$78.79k0.0039%
$ 117.0
Yael Margolin
Independent Director4.7yrsUS$87.02k0.0039%
$ 117.0
Mark Germain
Chairman of the Board6.4yrsUS$336.67kno data
Ruth Arnon
Head of Scientific Advisory Boardno datano datano data
George Lowell
Member of Scientific Advisory Boardno dataUS$68.36k0.013%
$ 371.7
Avner Rotman
Independent Director2.8yrsUS$76.59k0.0081%
$ 240.8
Michel Revel
Member of Scientific Advisory Boardno datano datano data
Samuel Moed
Director4.7yrsUS$493.15kno data
Jay Green
Independent Director2.9yrsUS$72.36k0.0025%
$ 74.2
Matthias Dobbelstein
Member of Scientific Advisory Board1.9yrsno datano data

4.7yrs

Average Tenure

71yo

Average Age

Experienced Board: SCNI's board of directors are considered experienced (4.7 years average tenure).